PUBLISHER: DelveInsight | PRODUCT CODE: 1226616
PUBLISHER: DelveInsight | PRODUCT CODE: 1226616
"STELARA Market Drug Insight and Market Forecast - 2032" report provides comprehensive insights about STELARA for Ulcerative Colitis (UC) in the seven major markets. A detailed picture of the STELARA for ulcerative colitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the STELARA for ulcerative colitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the STELARA market forecast analysis for ulcerative colitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ulcerative colitis.
STELARA is a human IgG1κ monoclonal antibody and a human interleukin-12 and -23 antagonist. Using DNA recombinant technology, ustekinumab is produced in a murine cell line (Sp2/0). The manufacturing process contains steps for the clearance of viruses. Ustekinumab comprises 1326 amino acids and has an estimated molecular mass that ranges from 148,079 to 149,690 Da.
Mechanism of action
Ustekinumab is a human IgG1 monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab was shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12RB1. The cytokines IL-12 and IL-23 have been implicated as important contributors to chronic inflammation - a hallmark of Crohn's disease and UC. In animal models of colitis, genetic absence or antibody blockade of the p40 subunit of IL-12 and IL-23, the target of ustekinumab, was shown to be protective.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
STELARA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of STELARA for ulcerative colitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of STELARA for ulcerative colitis covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions